|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 586 active entries
21 rue Bergère
Phone: +33 (0)1 53 40 8360
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
NewVectys is a biotech company specialized in innovative gene transfer technologies and their applications in transgenic large animal models and gene therapy. NewVectys portfolio is constantly enriched with new innovations in gene transfer technologies. Our R&D team works in close collaboration with some of the most advanced academic and private laboratories.
NewVectys activities cover the following areas:
We innovate in the field of vectorology to develop the most-advanced gene transfer tools such as new generations of lentiviral vectors with improved efficiency and safety features, site-specific integration systems, gene regulation or cell-type specific targeting.
NewVectys founding team is a recognized pioneer in the field of vectorology, with a strong track record including the filing of more than 40 patents and the publication of 100+ articles in international journals and reviews covering a variety of applications.
The innovation from our research in vectorology opens up new applications for NewVectys activities in gene therapy and transgenesis as well as for our clients and partners.
NewVectys offers a full range of solutions from initial design to breeding and experimentation for large transgenic animals to meet specific R&D needs.
Our transgenic models open-up new paths for therapeutic research and drug development. They provide a competitive advantage to our clients by accelerating the preclinical research process and enhancing innovation. Large animal models also contribute to reducing attrition thanks to higher quality of the models as large animals, such as the pig, are generally recognised more relevant to biomedical research than rodents. Reduced attrition results in lower cost, stronger and more efficient innovation process.
We co-develop advanced therapies pipelines from bench to patient. With our network of partners we develop breakthrough therapeutic strategies benefitting from our safe vector transfer technologies. For this we design front-edge vectors for clinical applications combining proven efficiency with highest safety.
Last update of this entry: February 01, 2012